Study of MRTX1719 in Solid Tumors With MTAP Deletion including NSCLC

Inclusion criteria:

  • Histologically confirmed diagnosis of a solid tumor malignancy with homozygous deletion of the MTAP gene detected in tumor tissue.
  • Unresectable or metastatic disease.
  • Presence of a tumor lesion amenable to mandatory biopsy for pharmacodynamic evaluation at baseline and on-study unless Sponsor-confirmed as medically unsafe or infeasible.

Sponsor/Collaborator: Bristol-Myers Squibb

Contact and Locations:
Name: BMS Clinical Trials Contact Center www.BMSClinicalTrials.com
Phone Number: 855-907-3286
Email: Clinical.Trials@bms.com
24 Locations (U.S.): https://www.clinicaltrials.gov/study/NCT05245500#contacts-and-locations

Mechanism of action: MRTX1719 is a potent PRMT5-MTA inhibitor.

Phases: Phase 1

NCT Number: NCT05245500

URL: https://www.clinicaltrials.gov/study/NCT05245500#study-plan

Status: Recruiting

Back to clinical trials list